NovImmune's Series C Round

NovImmune raised a round of funding on January 19, 2016. Investors include Fracht.

NovImmune is a biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer.…

Articles about NovImmune's Series C Round: